A Prospective, Single-center, Phase II Study of Sacituzumab Tirumotecan in Combination With Pembrolizumab for Neoadjuvant Treatment of Triple-Negative Breast Cancer (TNBC)

Clinical trial NCT07054242 · NOT_YET_RECRUITING

Trial details

NCT number: NCT07054242
Sponsor: Yantai Yuhuangding Hospital
Status: NOT_YET_RECRUITING
Phase: Phase 2
Study type: INTERVENTIONAL

Neoadjuvant Therapy Stage II to III (T1cN1-2 or T2-4N0-2) TNBC Breast Cancer

Start date: 2025-10-30
Primary completion: 2026-10-30
Enrollment: 52

View on ClinicalTrials.gov

Track trials programmatically

Sponsors, conditions and status changes through the Atlas API.